相关实验视频
Updated: Jan 17, 2026

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.9K
在阿尔茨海默病中,G蛋白结合受体 (GPCR) 与Tau蛋白相互作用
Subashchandrabose Chinnathambi1, Gowshika Velmurugan1, Vaishnavi Ananthanaraya1
1Department of Neurochemistry, National Institute of Mental Health and Neuro Sciences Hospital (NIMHANS), Institute of National Importance, Bangalore, Karnataka, India.
Advances in protein chemistry and structural biology
|September 19, 2025
概括
阿尔茨海默病涉及有毒的tau蛋白质寡合体. 向微质P2Y12受体可能会增强Tau清除并对抗神经退行.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 免疫学 免疫学 免疫学
背景情况:
- 阿尔茨海默氏病 (AD) 病理包括错误折叠的氨基酸β和蛋白.
- 寡合体是毒性物种,导致突触损失和神经退行.
- 微质细胞,大脑的免疫细胞,可以变得衰老,并促进AD的炎症.
研究的目的:
- 研究细胞外的Tau寡合体与微质纯能受体P2Y12.2之间的相互作用.
- 阐明P2Y12在调解微质对Tau寡合体反应中的作用.
- 确定P2Y12作为AD的潜在治疗点.
主要方法:
- 研究了tau寡合体与微质P2Y12的相互作用.
- 分析了P2Y12在微质迁移和动素重塑中的作用.
- 检查了P2Y12在Tau细胞分裂中的参与.
主要成果:
- 细胞外的Tau寡合体与微质P2Y12相互作用.
- 激活P2Y12会导致微质的迁移,动蛋白重塑 (filopodia,lamellipodia) 和细胞化.
- P2Y12调解寡合体诱导的微质化学反应.
结论:
- P2Y12在微质化学反应,动蛋白重塑和Tau清除中发挥着至关重要的作用.
- 准P2Y12为阿尔茨海默病提供了潜在的治疗策略.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825
G-protein Coupled Receptors
131.6K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
131.6K
Enzyme-linked Receptors
86.0K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
86.0K
Ligand-Gated Ion Channel Receptor: Gating Mechanism
3.8K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
3.8K

